|
**Overview**: Collagen Disease Antibodies Panel**Introduction**: The Collagen Disease Antibodies Panel is a diagnostic tool designed to screen for collagen vascular diseases using serum samples. In India, connective tissue diseases (SLE, scleroderma, Sjogren's, mixed CTD) affect ~0.5-1 percent of population, with higher prevalence in women. Antibodies (ANA, anti-dsDNA, anti-Smith, anti-Ro/La, anti-Scl-70, anti-Jo-1, anti-centromere, anti-RNP) aid specific diagnosis. High morbidity from underdiagnosis in rural/low-SES women, limited rheumatology access, delayed immunosuppression leading to organ damage (renal, pulmonary). Per immunology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for antibody panel over 1-2 days with high sensitivity/specificity, valuable for confirming CTD. This diagnostic falls under autoimmune screening and targets patients with joint pain, rash, Raynaud's, or organ symptoms, addressing accurate detection to guide therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Collagen Ab Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: ENA panel standard; in India, used in rheumatology clinics.**Purpose**: The test screens for 9 parameters including ANA to guide collagen vascular disease assessment, detect specific antibodies, inform treatment.**Test Parameters**: 1. ANA, 2. Anti-dsDNA, 3. Anti-Smith, 4. Anti-Ro, 5. Anti-La, 6. Anti-Scl-70, 7. Anti-Jo-1, 8. Anti-Centromere, 9. Anti-RNP.**Pretest Condition**: No fasting required; patients should report joint pain, rash, Raynaud's, or organ symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, organ involvement, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated CTD including organ damage, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibodies indicate CTD, necessitating specialist input. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Rheumatologists should be consulted for management.**Additional Supporting Tests**: Complement levels, biopsy for confirmation.**Test Limitations**: May miss rare antibodies; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, CTD Studies India 2023. |
